The FDA has approved Medicis’ hyaluronic acid with lidocaine dermal fillers, Restylane-L and Perlane-L. This approval was based on clinical data that demonstrated Restylane-L and Perlane-L to ...
Restylane Eyelight is the first and only product in the U.S. to use NASHA ® Technology to improve the appearance of undereye hollows for up to 18 months 1 DALLAS, June 5, 2023 /PRNewswire/ -- Galderma ...
SCOTTSDALE, Ariz., April 27, 2011 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the U.S. Food and Drug Administration's (FDA) General and Plastic Surgery Devices Advisory Panel (the ...
- Galderma reinforces long-term commitment to meet physician and patient needs in aesthetic and corrective dermatology worldwide Restylane, Perlane and Emervel are manufactured by Galderma and sold by ...
The FDA has approved Restylane® Kysse (Galderma) for lip augmentation and the correction of upper perioral rhytids in adults aged >21 years. The Food and Drug Administration (FDA) has approved ...
(MENAFN- PR Newswire) FORT WORTH, Texas, Sept. 30, 2021 /PRNewswire/ -- Galderma, the world's largest independent dermatology company, today marks the 25th anniversary of RESTYLANE®. Since launching ...
Evolus dermal filler, Evolysse™ Lift, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity ...
Men and nonsurgical facial procedures (i.e., in-office injectables, such as fillers like Restylane) are having a moment together—the numbers simply don't lie. Cosmetic surgery, as well as nonsurgical ...
"The first thing we look for is the ability to personalize treatment plans, because every face is different and has different needs," says Dr. Henry. One filler brand she says offers her "the tool kit ...
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results